Clinical trial • Phase I/II • Oncology

Pazopanib for Glioblastoma

Phase I/II trial of Pazopanib for Glioblastoma. 56 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Glioblastoma
Trial Stage
Phase I/II
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
31-01-2024
First CTIS Authorization Date
22-04-2024

Trial design

Phase I/II trial across 5 sites in France.

Target Sample Size
56

Recruitment

Planned Sample Size
56
Recruitment Window Months
197

Geography

Total Number Of Sites
5
Total Number Of Participants
56

France

Earliest CTIS Part Ii Submission Date
26-03-2024
Latest Decision Or Authorization Date
20-10-2025
Processing Time Days
573
Number Of Sites
5
Number Of Participants
56

Sites

Site Name
Assistance Publique Hopitaux De Marseille
Department Name
neuro-oncology
Contact Person Name
Emeline TABOURET
Contact Person Email
emeline.tabouret@ap-hm.fr
Site Name
Centre Antoine Lacassagne
Department Name
Oncology
Contact Person Name
Esma SAADA-BOUZID
Site Name
Institut De Cancerologie De L Ouest
Department Name
Oncology
Contact Person Name
Jean-Sébastien FRENEL
Site Name
Centre Hospitalier Universitaire De Nice
Department Name
Neurology
Contact Person Name
Véronique BOURG
Contact Person Email
bourg.v@chu-nice.fr
Site Name
Institut De Cancerologie De L Ouest
Department Name
Medical oncology
Contact Person Name
Paule AUGEREAU

Sponsor

Primary sponsor

Full Name
Centre Antoine Lacassagne
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
PAZOPANIB
Active Substance
Pazopanib
Modality
Small molecule
Routes Of Administration
oral
Route
oral
Investigational Product Name
TEMOZOLOMIDE
Active Substance
Temozolomide
Modality
Small molecule
Routes Of Administration
oral
Route
oral
Combination Treatment
Yes

Related trials

Other published trials that may interest you.